FDA delays Geron trial involving embryonic stem cells

05/14/2008 | Bloomberg

Geron Corp. on Wednesday received an oral notice from the FDA delaying its clinical trial of the GRNOPC1 stem cell compound in people with spinal cord injuries. The agency's move comes a month after advisers underscored the need for stricter safety measures in embryonic stem cell studies. The company said it is disappointed with the move and is awaiting a letter explaining the decision.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care